Premium
Neoadjuvant Nivolumab Safe, Led to Major Response Rates in Resectable Lung Cancer
Publication year - 2018
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.31672
Subject(s) - nivolumab , medicine , lung cancer , cancer , complete response , pathological , immunotherapy , oncology , neoadjuvant therapy , surgery , chemotherapy , breast cancer